Roche’s R&D is moving on up. The pharma giant has opened two new high-rises in Basel, Switzerland, according to a Sept. 10 ...
Roche is holding out hopes that its injectable obesity prospect could eventually demonstrate 25% weight loss in late-stage ...
Novo Nordisk has lifted the lid on a phase 1 trial of its oral amylin and GLP-1 receptor co-agonist, linking the candidate to ...
Shortly after a positive data drop for Eli Lilly’s efsitora a | Lilly revealed that its weekly insulin candidate efsitora ...
People with the Duffy null phenotype—who are primarily of African and Middle Eastern descent—have red blood cells that lack a ...
Just a few short weeks after winning an FDA Fast Track tag for its investigational BTK degrader in certain blood cancers, ...
GSK’s attempt to develop the first vaccine for herpes simplex virus (HSV) has ended in failure, leaving the race open for the ...
BridgeBio slashes gene therapy budget after early-phase data fall short of 'transformational' target
BridgeBio Pharma is slashing its gene therapy budget and pulling back from the modality after seeing the results of a phase 1 ...
The FDA has launched a study to examine the potential toxicity of metals that can be found within tampons—a regulated medical ...
The European Organization for Research and Treatment of Cancer (EORTC), a network of 3,800 members across 50 countries, is ...
SpectraWAVE has raised $50 million to support its approach to imaging the insides of clogged, plaque-filled blood vessels. | ...
The technique is called in vivo CAR-M therapy. "The nomination of the two autoimmune targets is a significant milestone in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results